|
Artgen, Inc. is a biotechnology company developing breakthrough treatments for vascular diseases. The company has a pipeline of preclinical therapeutic candidates with the first product (Art101) developed for treatment of Peripheral Arterial Disease (PAD). Founders: Maxim Tvishor, Irena Tsyrlova BHI Lead Contact: Albine Martin Investment: Maryland Industral Partnerships (MIPS), Human Stem Cells Institute (Seed Investment) *BHI Cofounded Company |
|